ADGM
Adagio Medical Holdings, Inc Common StockADGM
ADGM
About: Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for treatment of cardiac arrhythmias. The company focuses on developing innovative cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
0
Funds holding %
of 7,290 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
25% more funds holding
Funds holding: 12 [Q3] → 15 (+3) [Q4]
15.47% less ownership
Funds ownership: 89.77% [Q3] → 74.29% (-15.47%) [Q4]
63% less capital invested
Capital invested by funds: $31M [Q3] → $11.3M (-$19.7M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for ADGM.
Financial journalist opinion
Neutral
Business Wire
3 days ago
Adagio Medical Announces Strategic Restructuring to Accelerate US Pivotal IDE Trial and Product Innovation
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced a corporate restructuring and realignment of resources to prioritize its FULCRUM-VT US pivotal investigational device exemption (“Pivotal IDE”) clinical trial activities and its new product design optimization program. “After a comprehensive strategic review, we are doubling down on the pri.
Neutral
Business Wire
1 week ago
Adagio Medical to Participate at the TD Cowen's 45th Annual Health Care Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that management will be attending TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at the Marriott Copley Place in Boston, MA. About Adagio Medical Adagio Medical is an early commercial stage medical device company located in Laguna Hills, California focusing on deve.
Neutral
Business Wire
2 months ago
Adagio Medical Announces Appointment of Accomplished Medical Device Leader Todd Usen as Chief Executive Officer and Director
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company” or “Adagio”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that founder Olav Bergheim departed as Chief Executive Officer (“CEO”) and Chairperson of the Board of Directors of the Company, effective December 13, 2024. Concurrently, the Company announced the appointment of Todd Usen, as Chief Executive Officer and Director of the Company.
Neutral
Business Wire
3 months ago
Adagio Medical Reports Third Quarter 2024 Results
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company” or “Adagio”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced, today provided business updates for third quarter ended September 30, 2024. Recent Business Highlights: Reported total company revenue of $185 thousand in the third quarter of 2024, compared to $41 thousand in the third quarter of 2023. In September 2024, secured CMS coverage (.
Neutral
Business Wire
3 months ago
Adagio Medical to Present at the Stifel 2024 Healthcare Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that its CEO & President, Olav Bergheim, will present at the Stifel 2024 Healthcare Conference on Monday, November 18, at 9:45 a.m. Eastern Time in New York, NY at the Lotte New York Palace Hotel. A live audio webcast and replay of the presentation may be accessed on the “Investors” sec.
Neutral
Business Wire
4 months ago
Adagio Medical Announces Completion of First Procedures in FULCRUM-VT U.S. FDA Pivotal IDE of Ventricular Tachycardia Cryoablation System
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; “Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies, today announced the completion of the first procedures in FULCRUM-VT U.S. Food and Drug Administration (FDA) Pivotal IDE study of Adagio's VT Cryoablation System. Procedures were performed by Professor William G. Stevenson, MD, at Vanderbilt University Medical Center in Nashville, TN and Dr. J. David Burkhardt at.
Neutral
Business Wire
4 months ago
Adagio Medical Announces Participation in the 19th Annual International Symposium on Ventricular Arrhythmias
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced its sponsorship and participation in the 19th Annual International Symposium on Ventricular Arrhythmias, to be held at the New York Marriott at the Brooklyn Bridge on October 11-12, 2024. In addition to participating in the commercial exhibition, Adagio's proprietary Ultra-Low Temperature C.
Neutral
Business Wire
6 months ago
Adagio Medical Provides Business Updates
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at.
Charts implemented using Lightweight Charts™